Other specified acantholytic disorders
ICD-10 L11.8 is a billable code used to indicate a diagnosis of other specified acantholytic disorders.
L11.8 refers to other specified acantholytic disorders, which are characterized by the loss of connections between keratinocytes, leading to the formation of blisters and erosions in the skin. These disorders can affect various anatomical regions, including the epidermis and dermis, and may present with symptoms such as pruritus, erythema, and vesicular lesions. Acantholytic disorders can be idiopathic or secondary to other conditions, including autoimmune diseases or drug reactions. Disease progression varies, with some patients experiencing acute episodes while others may have chronic manifestations. Diagnostic considerations include a thorough clinical examination, histopathological evaluation through skin biopsy, and serological tests to rule out associated autoimmune conditions. Accurate diagnosis is crucial for effective management and treatment, which may involve topical therapies, systemic medications, or immunosuppressive agents depending on the severity and underlying cause of the disorder.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
L11.8 encompasses various acantholytic disorders not classified elsewhere, including but not limited to pemphigus vulgaris, drug-induced acantholysis, and certain forms of epidermolysis bullosa. Each condition has specific diagnostic criteria based on clinical presentation and histological findings.
L11.8 should be used when the acantholytic disorder does not fit the definitions of more specific codes. It is essential to differentiate based on clinical findings and histopathological results to ensure accurate coding.
Documentation should include a detailed clinical history, physical examination findings, results from skin biopsies, and any laboratory tests performed. Clear notes on the patient's response to treatments and any comorbid conditions are also necessary.
